• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

了解糖尿病对骨骼健康的影响:一项临床综述。

Understanding the impact of diabetes on bone health: A clinical review.

作者信息

Sharma Preeti, Sharma Rahul Kumar, Gaur Khushboo

机构信息

Department of Pharmacy, PSIT-Pranveer Singh Institute of Technology (Pharmacy), Bhauti, Kanpur, 209305, Uttar Pradesh, India.

Aryakul College of Pharmacy & Research Sitapur, Village- Jajjaur, Post- Manawa, (Near Krishi Vigyan Kendra Sitapur) Sidhauli, Dist- Sitapur- 261303 U.P, India.

出版信息

Metabol Open. 2024 Nov 8;24:100330. doi: 10.1016/j.metop.2024.100330. eCollection 2024 Dec.

DOI:10.1016/j.metop.2024.100330
PMID:39606009
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11600011/
Abstract

Diabetic bone disease, a form of secondary osteoporosis, is characterized by weakened bones and an increased risk of fractures, especially in patients with type 2 diabetes (T2D). This review explores the key mechanisms driving this condition, including hyperglycemia, insulin resistance, advanced glycation end products (AGEs), and proinflammatory cytokines, all of which disturb normal bone turnover by disrupting the functions of osteoblasts and osteoclasts. We examine the roles of bone turnover and mineralization, as well as how microvascular complications affect bone microarchitecture. Additionally, the influence of gut hormones, such as GLP-1 and GIP, and gut microbiota, particularly species like , on the gut-bone axis is discussed, as these factors play a role in regulating bone density and structure. While T2D patients may show normal or even elevated bone mineral density (BMD), the underlying quality of bone is often compromised, leading to increased fragility. This review integrates current knowledge on the molecular, hormonal, and microbial interactions contributing to diabetic bone disease. By highlighting these pathways, we aim to offer insights into potential therapeutic strategies and inform future research aimed at improving the diagnosis, treatment, and overall management of this condition.

摘要

糖尿病性骨病是继发性骨质疏松症的一种形式,其特征是骨骼变弱以及骨折风险增加,尤其是2型糖尿病(T2D)患者。本综述探讨了导致这种病症的关键机制,包括高血糖、胰岛素抵抗、晚期糖基化终末产物(AGEs)和促炎细胞因子,所有这些都会通过破坏成骨细胞和破骨细胞的功能来干扰正常的骨转换。我们研究了骨转换和矿化的作用,以及微血管并发症如何影响骨微结构。此外,还讨论了肠道激素(如胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽)和肠道微生物群(特别是诸如某些物种)对肠-骨轴的影响,因为这些因素在调节骨密度和结构中发挥作用。虽然T2D患者可能表现出正常甚至升高的骨矿物质密度(BMD),但其潜在的骨质量往往受损,导致脆性增加。本综述整合了有关导致糖尿病性骨病的分子、激素和微生物相互作用的现有知识。通过强调这些途径,我们旨在提供对潜在治疗策略的见解,并为未来旨在改善这种病症的诊断、治疗和整体管理的研究提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11600011/0154a32d1968/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11600011/0154a32d1968/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef45/11600011/0154a32d1968/gr1.jpg

相似文献

1
Understanding the impact of diabetes on bone health: A clinical review.了解糖尿病对骨骼健康的影响:一项临床综述。
Metabol Open. 2024 Nov 8;24:100330. doi: 10.1016/j.metop.2024.100330. eCollection 2024 Dec.
2
Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength.2 型糖尿病中骨经典 Wnt 信号通路下调,与更高的晚期糖基化终产物(AGEs)含量和骨强度降低相关。
Elife. 2024 Apr 10;12:RP90437. doi: 10.7554/eLife.90437.
3
Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.2型糖尿病老年女性骨骼中的硬化蛋白调节、微结构与晚期糖基化终产物
J Bone Miner Res. 2020 Dec;35(12):2415-2422. doi: 10.1002/jbmr.4153. Epub 2020 Oct 2.
4
Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus.肠道衍生肽激素类似物与肥胖症和糖尿病中骨疾病的潜在治疗
Clin Med Insights Endocrinol Diabetes. 2024 Mar 13;17:11795514241238059. doi: 10.1177/11795514241238059. eCollection 2024.
5
Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.胃抑制肽、胰高血糖素样肽-1 和胰高血糖素样肽-1 受体激动剂对骨细胞代谢的影响。
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):25-37. doi: 10.1111/bcpt.12850. Epub 2017 Aug 11.
6
Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.糖尿病性骨质疏松中晚期糖基化终产物(AGEs)的作用。
Curr Drug Targets. 2011 Dec;12(14):2096-102. doi: 10.2174/138945011798829456.
7
Induction and rescue of skeletal fragility in a high-fat diet mouse model of type 2 diabetes: An in vivo and in vitro approach.2 型糖尿病高脂肪饮食小鼠模型中骨脆弱的诱导和挽救:一种体内和体外方法。
Bone. 2022 Mar;156:116302. doi: 10.1016/j.bone.2021.116302. Epub 2021 Dec 21.
8
Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts.香豆素通过抑制糖尿病成骨细胞和破骨细胞中晚期糖基化终产物的形成来改善骨代谢紊乱。
Biomolecules. 2020 Jul 15;10(7):1052. doi: 10.3390/biom10071052.
9
Diabetes and Bone.糖尿病与骨骼
Semin Musculoskelet Radiol. 2016 Jul;20(3):300-304. doi: 10.1055/s-0036-1592366. Epub 2016 Oct 14.
10
Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification.晚期糖基化终产物和氧化应激在2型糖尿病所致骨脆性中的作用及其对骨折风险分层的影响
Antioxidants (Basel). 2023 Apr 14;12(4):928. doi: 10.3390/antiox12040928.

引用本文的文献

1
10-Year Fracture Risk Assessment with Novel Adjustment (FRAXplus): Type 2 Diabetic Sample-Focused Analysis.采用新型调整方法的10年骨折风险评估(FRAXplus):以2型糖尿病样本为重点的分析。
Diagnostics (Basel). 2025 Jul 29;15(15):1899. doi: 10.3390/diagnostics15151899.
2
Risk factors for refracture or new vertebral compression fractures after percutaneous vertebroplasty: a systematic review and meta-analysis.经皮椎体成形术后再骨折或新发椎体压缩骨折的危险因素:一项系统评价和Meta分析
Osteoporos Int. 2025 Jun 11. doi: 10.1007/s00198-025-07523-z.
3
A cross-sectional study on the correlation between fasting blood glucose and bone turnover markers in Chinese patients with osteoporotic fractures.
中国骨质疏松性骨折患者空腹血糖与骨转换标志物相关性的横断面研究。
Front Med (Lausanne). 2025 Apr 10;12:1564957. doi: 10.3389/fmed.2025.1564957. eCollection 2025.